Rankings / Sleep & Recovery

LL-37 (cathelicidin)

Sleep & Recovery · Antimicrobial peptide

Tier D

peptide
3.3 / 10
Tier D
Ev 2 Bn 5 Sf 4

Bottom line

Read Off Label grades LL-37 (cathelicidin) as D (3.3/10) based on preclinical evidence, unclear benefit magnitude, and a unclear-risk safety profile.

Used by some protocols targeting biofilm-associated chronic infections (CIRS/Lyme communities).

Typical use: No established human dosing protocol — Not FDA-approved; research peptide.

What this is

Used by some protocols targeting biofilm-associated chronic infections (CIRS/Lyme communities). Essentially no clinical trial safety data in humans for exogenous administration. Speculative application.

Mechanism

Endogenous cationic host-defense peptide from cathelicidin; broad antimicrobial activity; immunomodulatory and wound healing effects; VDR-regulated

Dose & route

No established human dosing protocol

Common questions

Does LL-37 (cathelicidin) work?
Read Off Label rates the evidence for LL-37 (cathelicidin) as Preclinical and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). Used by some protocols targeting biofilm-associated chronic infections (CIRS/Lyme communities).
Is LL-37 (cathelicidin) safe?
LL-37 (cathelicidin) has a unclear risk profile in published human data. Legal status: Not FDA-approved; research peptide. This is not medical advice — see the disclaimer.
What is the typical dose for LL-37 (cathelicidin)?
No established human dosing protocol
How does LL-37 (cathelicidin) work?
Endogenous cationic host-defense peptide from cathelicidin; broad antimicrobial activity; immunomodulatory and wound healing effects; VDR-regulated

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.